From owner-dros@hgmp.mrc.ac.uk Wed Sep 10 14:56:57 2003 Return-Path: X-Original-To: dros-outgoing Received: from localhost (localhost [127.0.0.1]) by mercury.hgmp.mrc.ac.uk (Postfix) with SMTP id 7E5217D11D for ; Wed, 10 Sep 2003 14:56:57 +0100 (BST) X-Original-To: dros-list@hgmp.mrc.ac.uk Received: from localhost (localhost [127.0.0.1]) by mercury.hgmp.mrc.ac.uk (Postfix) with ESMTP id 0406C7D0CB for ; Wed, 10 Sep 2003 14:56:57 +0100 (BST) Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 6020) id ADBB67D11D; Wed, 10 Sep 2003 14:56:54 +0100 (BST) X-Original-To: bionet-drosophila@net.bio.net Received: from localhost (localhost [127.0.0.1]) by mercury.hgmp.mrc.ac.uk (Postfix) with ESMTP id A8BE77D0C9 for ; Mon, 8 Sep 2003 13:35:10 +0100 (BST) Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 60001) id 9AD077D334; Mon, 8 Sep 2003 13:35:08 +0100 (BST) To: bionet-drosophila@net.bio.net From: laura.wood@researchandmarkets.com ("=?iso-8859-1?Q?Laura_Wood?=") Newsgroups: bionet.drosophila Subject: =?iso-8859-1?Q?Proteomics_2003?= Organization: BIOSCI/MRC Human Genome Mapping Project Resource Centre Message-ID: charset="iso-8859-1" X-Original-To: dros@net.bio.net X-Received: from localhost (localhost [127.0.0.1]) by mercury.hgmp.mrc.ac.uk (Postfix) with ESMTP id 1EACF7D0C9 for ; Mon, 8 Sep 2003 13:35:07 +0100 (BST) X-Received: from FRODO (unknown [62.17.245.34]) by mercury.hgmp.mrc.ac.uk (Postfix) with ESMTP id B95FB7D333 for ; Mon, 8 Sep 2003 13:35:00 +0100 (BST) X-Received: from mail pickup service by FRODO with Microsoft SMTPSVC; Mon, 8 Sep 2003 13:36:06 +0100 X-To: "=?iso-8859-1?Q?dros@net=2Ebio=2Enet?=" X-Priority: 3 X-MSMail-Priority: Normal X-Mailer: JMail 4.3.1 by Dimac X-OriginalArrivalTime: 08 Sep 2003 12:36:06.0406 (UTC) FILETIME=[C5ECF260:01C37605] Date: Wed, 10 Sep 2003 14:56:54 +0100 (BST) Sender: owner-dros@hgmp.mrc.ac.uk Precedence: bulk I enclose details of our latest Proteomics report. Proteomics technologies have dramatically accelerated the study of proteins, resulting in the discovery of thousands of potential biomarkers and drug targets. Further advances, primarily in mass spectrometry, are expected to increase the rate of discovery. The proteomics market grew from $1.1 billion in 2001 to almost $1.4 billion in 2002 and, based on first quarter numbers, the growth rate is continuing in 2003. But the success is creating a bottleneck. High-throughput and/or high-output technologies are used to discover potential biomarkers and drug targets, but the validation methods are low-throughput and low-output. For proteomics to continue its current growth rate, the industry needs new methods and technologies to speed validation. Fortunately, multiple emerging technologies are poised to meet this need. The report, Proteomics 2003, presents detailed interviews with proteomics experts, thorough evaluations of 75 leading proteomics companies in the United States and Europe, three scenarios for the future of the industry, and a quantitative market model. The analysis is based on extensive research that includes dozens of interviews with current and potential customers and with company representatives. Proteomics 2003 reveals the insights of experts regarding unmet needs and future directions of the industry. Despite the range of opinions and practices, the experts all agreed about the developing bottleneck. The report also evaluates the strengths and weaknesses of each of the proteomics companies, and assesses both opportunities and threats facing their products and services. Proteomics 2003 identifies the companies most likely to dominate specific market segments, as well as the companies most likely to play key supporting roles in moving technologies forward. Proteomics 2003 presents a pessimistic, a cautiously optimistic, and an optimistic scenario for the growth of the industry. Even in the worst case, the market holds its ground; in the best case, proteomics dramatically accelerates drug discovery and development and extends this success into diagnostics. Proteomics 2003 divides the market into the three different applications. The first is discovery and validation of drug targets and biomarkers, in which researchers use proteomics technologies to discover and, to a much lesser extent, to validate the roles of specific proteins in disease processes. The second application is drug development, in which researchers transform drug targets into potential therapeutics. The third application is clinical trials and diagnostics, in which scientists strive to use proteomics technologies to identify and monitor disease states and drug responses. At the same time, the report examines how each of these applications employs the four classes of proteomics technologies. (1) Mass spectrometry systems are used to detect proteins based on the charge/mass ratio of peptides, and to identify proteins by comparing this ratio to a database of predicted values. (2) Protein separation divides the proteome into manageable units. The primary methods are 2-D gel electrophoresis and chromatography. After separation, the proteins are commonly identified by mass spectrometry. (3) Parallelized screening methods analyze proteins in parallel, and generally have higher throughput than other proteomics methods. The primary technologies are based on beads or biochips. (4) Functional proteomics includes a family of innovative methods for high-output and/or high-throughput analysis of protein function. For a complete index of this report click on http://www.researchandmarkets.com/reports/30017 Report Index: Chapter 1: Executive Summary 8 Introduction 9 Applications 10 Interviews with Experts 11 Competitive Environment 12 State of the Market in 2003 13 Successes 13 Challenges 14 Scenarios 16 Market Size 17 Total 17 By Technology 18 By Applications 19 Chapter 2: Technology 20 Introduction 21 Output versus Throughput 22 Mass Spectrometry 23 Introduction 23 Ionization Methods 24 Mass Analysis Methods 25 Common Instrument Configurations 27 A Typical Proteomic Analysis 28 Quantitative Methods 29 Protein Separation 30 2-D Gel Electrophoresis 30 Chromatography 31 Parallelized Screening Methods 32 Protein Biochips 32 Bead-Based Methods 34 Functional Proteomics 35 Overview 35 Map 36 Chapter 3: Applications 37 Expression and Function 38 Target/Biomarker Discovery 39 Target/Biomarker Validation 40 Drug Development 42 Clinical Trials/ Diagnostics 45 Chapter 4: Interviews with Experts 47 Introduction 48 Successes 49 Challenges 50 The Looming Validation Bottleneck 51 Expert 1 52 Expert 2 56 Expert 3 59 Expert 4 62 Expert 5 65 Expert 6 66 Expert 7 68 Expert 8 70 Expert 9 72 Expert 10 74 Chapter 5: Company Evaluations 76 Mass Spectrometry 77 Agilent Technologies Inc. 78 Applied Biosystems Group 80 Bruker Daltonics, Inc. 82 PerkinElmer Life Sciences 84 Shimadzu Biotech 87 Target Discovery, Inc. 89 Thermo Finnigan 91 Waters Corporation 93 Protein Separation 95 Amersham Biosciences 96 Beckman Coulter, Inc. 98 Bio-Rad Laboratories, Inc. 100 Parallelized Screening Methods 105 Affibody AB 106 Archemix Corporation 107 Aspira Biosystems, Inc. 110 BD Biosciences 113 Biacore International AB 116 BioForce Nanosciences, Inc. 118 BioInvent International AB 121 Biosite Incorporated 123 Cambridge Antibody Technology Group plc 126 Ciphergen Biosystems, Inc. 128 CombiMatrix 131 Corning Incorporated Life Sciences 134 Discerna Ltd. 136 Domantis Limited 138 GeneScan Europe AG 139 HTS Biosystems, Inc. 142 Hypromatrix, Inc. 145 Jerini AG 147 Large Scale Biology Corporation 151 Eurogentec Proteomics GmbH 151 Proteome Systems Ltd. 1%3 LumiCyte, Inc. 154 Luminex Corporation 156 Molecular Staging Inc. 158 nanotype GmbH 160 NextGen Sciences Ltd. 163 Pepscan Systems BV 167 Phylos, Inc. 170 Procognia Ltd. 172 Protagen AG 174 ProteinOne Inc. 177 Protiveris Inc. 179 Protometrix, Inc. 181 Randox Laboratories Ltd. 185 SomaLogic, Inc. 187 TeleChem International, Inc. 190 VBC-GENOMICS Bioscience Research GmbH 193 Zeptosens AG 195 Zyomyx, Inc. 198 LumiCyte, Inc. 154 Luminex Corporation 156 Molecular Staging Inc. 158 nanotype GmbH 160 NextGen Sciences Ltd. 163 Pepscan Systems BV 167 Phylos, Inc. 170 Procognia Ltd. 172 Protagen AG 174 ProteinOne Inc. 177 Protiveris Inc. 179 Protometrix, Inc. 181 Randox Laboratories Ltd. 185 SomaLogic, Inc. 187 TeleChem International, Inc. 190 VBC-GENOMICS Bioscience Research GmbH 193 Zeptosens AG 195 Zyomyx, Inc. 198 Chapter 6: Market Model 258 State of the Market in 2003 259 Successes 259 Challenges 260 Scenarios 262 Total Market 263 Companies 263 Size 267 Market Model Methodology 268 Research and Analysis 268 Quantitation 269 Market Segmentation 270 Market Definitions 271 Market Inclusions and Exclusions 272 Market By Technology 273 Drivers 273 Size and Shares 274 Market By Data Type 275 Drivers 275 Size and Shares 276 Market By Applications 277 Drivers 277 Size and Shares 278 Report Pricing: Hard Copy EUR 5,297 Electronic EUR 6,153 Site Licence EUR 6,153 ORDERING - FOUR EASY WAYS TO PLACE YOUR ORDER: Order online: To order this report please click on http://www.researchandmarkets.com/reports/30017 Order via email: mailto:orders@researchandmarkets.com Order via fax-back form: Click on http://www.researchandmarkets.com/reports/30017 Fax to +353 1 4100 980 Order via post: Click on http://www.researchandmarkets.com/reports/30017 Mail to Research and Markets Ltd., Guinness Centre, Taylors Lane, Dublin 8, Ireland Related Reports Available from Research & Markets Ltd: Proteomics: Analysis of Selected Emerging Technologies - http://www.researchandmarkets.com/reports/412 Proteomics: A Key Enabling Tool for Genomics? - http://www.researchandmarkets.com/reports/417 Proteomics Survey Report 2003 - http://www.researchandmarkets.com/reports/19843 Protein Kinases: Technologies and Opportunities for Drug Discovery - http://www.researchandmarkets.com/reports/29257 Human Genome: Its future - http://www.researchandmarkets.com/reports/28549 Cancer Genomics: Evolving Terminology for Emerging Technologies - http://www.researchandmarkets.com/reports/10814 Functional Proteomics and Emerging Bio-IT Market - http://www.researchandmarkets.com/reports/16635 Proteomics and Bioethics: The Future of the Human Genome - http://www.researchandmarkets.com/reports/4047 Structural Proteomics: High-Throughput Approaches Fuel Drug Discovery & Development - http://www.researchandmarkets.com/reports/411 GPCRs: The Targets of Today's Drugs and Tomorrow's Blockbusters - http://www.researchandmarkets.com/reports/4043 Protein Biochips 2003 - http://www.researchandmarkets.com/reports/28460 Life Sciences Informatics: From Data to Drugs - http://www.researchandmarkets.com/reports/19842 Profiting from Proteomics: Entering the Age of High-Throughput - http://www.researchandmarkets.com/reports/401 Click on http://www.researchandmarkets.com for details. Thank you for your consideration. Kind Regards, Laura Wood Senior Manager Research and Markets Ltd laura.wood@researchandmarkets.com REPORT DATA SUMMARY: Proteomics 2003 Publisher Name: Select Biosciences Ltd Date Published: 07/07/03 Number of Pages: 278 Category: Proteomics URL: www.researchandmarkets.com/reports/30017 Subscribe: Click on http://www.researchandmarkets.com/register.asp You can subscribe free for regular details on new research in your sector. If you no longer wish to receive our market research updates, please reply to this message with "Suppression Request" as the subject line, or email a blank email to suppressed@researchandmarkets.com or access our unsubscribe page at: http://www.researchandmarkets.com/unsubscribe.asp --- .